HC Wainwright Forecasts Lower Earnings for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at HC Wainwright cut their Q2 2026 EPS estimates for shares of TG Therapeutics in a research note issued to investors on Monday, July 13th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings of $0.22 per share for the quarter, down from their prior forecast of $0.36. HC Wainwright currently has a “Buy” rating and a $77.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $1.46 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q3 2026 earnings at $0.28 EPS, FY2026 earnings at $0.99 EPS, FY2028 earnings at $3.81 EPS, FY2029 earnings at $4.70 EPS and FY2030 earnings at $5.84 EPS.

Other analysts have also issued reports about the company. Bank of America boosted their target price on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Finally, Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $53.33.

TG Therapeutics Price Performance

TGTX stock opened at $54.93 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12. The company’s 50-day moving average is $47.51 and its 200-day moving average is $37.03. The stock has a market capitalization of $8.41 billion, a PE ratio of 19.21, a price-to-earnings-growth ratio of 1.41 and a beta of 1.60. TG Therapeutics has a 1 year low of $25.28 and a 1 year high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The company had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. During the same quarter in the previous year, the business posted $0.03 earnings per share. The company’s revenue for the quarter was up 69.5% compared to the same quarter last year.

Institutional Trading of TG Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Congress Asset Management Co. bought a new stake in TG Therapeutics during the fourth quarter worth $57,307,000. Man Group plc increased its position in shares of TG Therapeutics by 621.5% during the 3rd quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock valued at $36,431,000 after purchasing an additional 868,697 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of TG Therapeutics by 856.6% during the 4th quarter. BNP Paribas Financial Markets now owns 683,653 shares of the biopharmaceutical company’s stock valued at $20,380,000 after purchasing an additional 612,189 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of TG Therapeutics by 129.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock worth $36,029,000 after purchasing an additional 612,068 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of TG Therapeutics by 71.7% during the 1st quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock worth $48,544,000 after purchasing an additional 610,195 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: H.C. Wainwright reiterated a Buy rating on TG Therapeutics and maintained a $77 price target, signaling confidence in the company’s growth potential. TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright
• Positive Sentiment: H.C. Wainwright raised its longer-term earnings forecasts for FY2028, FY2029, and FY2030, suggesting expectations for improving profitability over time.
• Neutral Sentiment: Another recent report noted analysts are split on TG Therapeutics, reinforcing that sentiment around the name remains mixed rather than universally bullish. Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)
• Neutral Sentiment: H.C. Wainwright also trimmed some near-term EPS estimates for Q2, Q3, and FY2026, indicating expectations for softer earnings in the short run even though the long-term outlook improved.
• Negative Sentiment: Bank of America Securities kept a Sell rating on TG Therapeutics, adding a bearish counterpoint that may weigh on investor sentiment. Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.